ArticleJournal of vascular surgery2025
Outcomes associated with type II endoleaks after infrarenal endovascular aneurysm repair in the Vascular Quality Initiative linked to Medicare claims.
Article in Journal of vascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanism-guided endograft explantation eliminates shear-mediated aortic injury in a controlled simulation study.Journal of vascular surgery cases and innovative techniques · 2026Article
- Percutaneous transosseous approach for type II endoleak repair of common iliac artery aneurysm.Radiology case reports · 2026Article
- Ensuring Reproducibility in Endovascular Aneurysm Repair: Clinical Impact of Prophylactic Branch Embolization in a Low-Volume Setting.Annals of vascular diseases · 2026Article
- EndoEx: Benchtop and cadaveric evaluation of a novel endograft removal device.Journal of vascular surgery cases and innovative techniques · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveType II endoleaks (T2ELs) are commonly identified after endovascular aneurysm repair (EVAR) and may occur either at the completion of the procedure or during follow-up. However, the impact of T2EL on reintervention and survival remains poorly described. This study aims to evaluate the outcomes associated with T2EL in a real-world cohort using the Vascular Quality Initiative linked Medicare claims (Vascular Quality Initiative-Medicare) database.
methodsWe retrospectively reviewed all elective EVARs in the Vascular Quality Initiative-Medicare (part of the Vascular Implant Surveillance and Interventional Outcomes coordinated registry network) database from 2010 to 2018. Patients with Medicare fee-for-service entitlement at the time of the index procedure and continuous entitlement during follow-up were included. We excluded patients with endoleaks other than T2EL at completion or follow-up, those with missing T2EL status at completion, and patients with no imaging follow-up. The primary outcomes were aneurysm-related reintervention, freedom from rupture, and overall survival. A time-dependent analysis based on the T2EL status and Cox proportional hazards multivariable models were used to assess associations between T2EL and the outcomes.
resultsA total of 8195 patients were included in the final analysis, with 6653 (81%) in the no T2EL group and 1542 (19%) in the T2EL group. Patients in the T2EL group were older (76 years vs 75 years; P = .006) and had lower rates of active smoking (21% vs 26%; P < .001), chronic obstructive pulmonary disease (28% vs 32%; P = .003), congestive heart failure (9% vs 12%; P = .004), and a history of prior vascular intervention. At 5 years, the rate of aneurysm-related reintervention was significantly higher in the T2EL group (30.4% vs 11%; P < .0001); however, there was no significant difference in freedom from rupture between the groups (95.6% vs 98.2%, adjusted hazard ratio [aHR], 0.98, 95% confidence interval [CI]. 0.5-2.0). Unadjusted overall survival rates at 5 years were similar between the groups (74% vs 71%). On multivariate regression analysis, the presence of a T2EL was not associated with an increased risk of mortality (aHR, 0.83; 95% CI, 0.69-1.01; P = .057). Subgroup analysis in patients with T2EL showed that reintervention was not significantly associated with overall survival at 5-years (aHR, 0.45; 95% CI, 0.1-1.9; P = .27).
conclusionsT2EL occurred in nearly one-fifth of patients after EVAR and was associated with a higher rate of reintervention compared with patients without T2EL. Yet, reinterventions were not linked to better survival. Thus, the overall benefit of reintervention for isolated T2EL in current practice remains to be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.